Rep. Pete Aguilar

Break Free From Plastic Pollution Act of 2021 This bill sets forth requirements and incentives to reduce the production of a variety of products and materials, including plastics, and increase efforts to collect, recycle, or compost products and materials. The bill makes certain producers of products (e.g., packaging, paper, single-use products, beverage containers, or food service products) fiscally responsible for collecting, managing, and recycling or composting the products after consumer use. In addition, the bill establishes (1) minimum percentages of products that must be reused, recycled, or composted; and (2) an increasing percentage of recycled content that must be contained in beverage containers. Beginning on January 1, 2023, the bill phases out a variety of single-use products, such as plastic utensils. The bill also sets forth provisions to encourage the reduction of single-use products, including by establishing programs to refund consumers for returning beverage containers and by establishing a tax on carryout bags. The bill creates a temporary moratorium on new or expanded permits for certain facilities that manufacture plastics until regulations are updated to address pollution from the facilities. The Environmental Protection Agency (EPA) must publish guidelines for a national standardized labeling system for recycling and composting receptacles. Producers must include labels on their products that are easy to read and indicate whether the products are recyclable, compostable, or reusable. The EPA must also ensure that certain clothes washers have filtration units as required by this bill. Finally, the bill establishes limitations on the export of plastic waste to other countries.

Health Equity and Accountability Act of 2022 This bill directs the Department of Health and Human Services (HHS) and others to undertake efforts to reduce health disparities. For example, the bill (1) requires more detailed reporting of demographic and health disparities data, including related to public health emergencies; (2) directs certain components of HHS to support health workforce diversity; and (3) increases access to culturally and linguistically appropriate health care. The bill also modifies eligibility and other requirements for Medicare, Medicaid, private health insurance, nutrition assistance, and other programs to reduce health disparities among vulnerable populations. The bill includes specific provisions with respect to noncitizens; maternal, infant, and child health; mental and behavioral health; specified conditions that disproportionately affect racial and ethnic minority groups, such as certain cancers, HIV/AIDS, kidney disease, and diabetes; investments in communities facing health and other inequities; and nondiscrimination in the provision of services in federally supported health programs. Additionally, the bill (1) revises health information technology programs to address health disparities, and (2) supports health impact assessments and other efforts pertaining to environmental justice and social determinants of health (i.e., nonmedical factors that influence health outcomes, such as income and educational attainment). The bill also requires various studies and reports on issues related to health care and health disparities, including a report by the Government Accountability Office on health workforce diversity.

Telemental Health Parity Act of 2022 This bill requires private health insurance plans to apply benefits for mental health or substance use disorder services that are furnished via telehealth in the same manner as those services that are furnished in person. Under current mental health parity rules, insurance plans that provide benefits for mental health or substance use disorder services are generally required to make those benefits comparable to the benefits the plan provides for medical and surgical care.

This bill designates the facility of the United States Postal Service located at 502 East Cotati Avenue in Cotati, California, as the Arturo L. Ibleto Post Office Building.

My Body, My Data Act of 2022 This bill establishes protections, subject to certain limits, for personal reproductive or sexual health information. This includes information relating to past, present, or future surgeries or procedures, such as the termination of a pregnancy. Specifically, commercial entities, including individuals, nonprofits, and common carriers, may not collect, retain, use, or disclose personal reproductive or sexual health information except (1) with the express written consent of the individual to whom such information relates, or (2) as is strictly necessary to provide a requested product or service. Commercial entities also must provide individuals with access to, and a reasonable mechanism to delete, any of their reproductive or sexual health information upon request. Further, commercial entities must maintain and publish a privacy policy describing their practices with respect to such information. The bill's provisions do not apply to entities that are subject to certain existing health-related privacy regulations, such as the privacy regulations issued under the Health Insurance Portability and Accountability Act of 1996. Additionally, the provisions do not apply to the disclosure of personal reproductive or sexual health information for the publication of newsworthy information of legitimate public concern. The bill provides for enforcement by the Federal Trade Commission and by private civil actions.

Advanced Research Project s Agency-Health Act or the ARPA-H Act This bill establishes within the Department of Health and Human Services (HHS) the Advanced Research Projects Agency-Health to accelerate health and medical innovation by investing in high-risk, high-reward research. The bill also establishes a committee to advise on agency activities. HHS must transfer all authorities, functions, funds, and personnel from a similar entity within the National Institutes of Health to a new, independent agency. Additionally, the President must appoint a director to lead the agency. The director may submit testimony and recommendations concerning the agency to Congress without review or approval by other federal officers or agencies. The director must appoint personnel to administer the agency's research programs, including by selecting projects to support and making recommendations about terminating or continuing projects. The agency may use grants, prize competitions, and a variety of other mechanisms to support the research projects. The agency's budget is separate from that of HHS. The agency must coordinate with the Food and Drug Administration and the Centers for Medicare & Medicaid Services to expedite development and coverage of high-need cures. Additionally, the agency may partner with other public and private entities (e.g., institutions of higher education and patient advocacy organizations). The bill also requires the agency to develop and periodically update a strategic plan and annually report on its activities. Furthermore, (1) the National Academies of Sciences, Engineering, and Medicine must evaluate the agency's performance; and (2) the Government Accountability Office must review the research portfolio of HHS and its components, including the new agency.

Save America’s Forgotten Equines Act of 2021 or the SAFE Act of 2021 This bill prohibits the transporting, receiving, possessing, purchasing, selling, or donation by a person of an equine (e.g., horse) that the person has reason to believe will be slaughtered for human consumption.

This bill designates the facility of the United States Postal Service located at 1 League in Irvine, California, as the Tuskegee Airman Lieutenant Colonel Robert J. Friend Memorial Post Office Building.

This resolution commends U.S. Capitol Police Officer Caroline Edwards for protecting Members of Congress, staff, and others during the events of January 6, 2021.

Saving Access to Laboratory Services Act This bill modifies provisions relating to Medicare payment rates for clinical diagnostic laboratory services, including by requiring payment rates for certain widely available clinical diagnostic laboratory tests to be based on a statistical sampling of private sector rates.